PMID- 8586321
OWN - NLM
STAT- MEDLINE
DCOM- 19960322
LR  - 20180216
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 25
IP  - 6
DP  - 1995 Nov-Dec
TI  - One-year experience of very low doses of subcutaneous erythropoietin in 
      continuous ambulatory peritoneal dialysis and its effect on haemostasis.
PG  - 299-304
AB  - Recombinant human erythropoietin (rHuEpo) is now well established in the 
      management of the anaemia associated with chronic renal failure. The aim of this 
      study was to assess the efficacy and safety of low doses of subcutaneous (s.c.) 
      erythropoietin in continuous ambulatory peritoneal dialysis (CAPD) patients and 
      particularly its effects on haemostasis. Seven CAPD patients were given s.c. 
      erythropoietin for more than 1 year. Their mean age was 36.2 +/- 9.2 years and 
      their mean pretreatment haemoglobin (Hb) was 7.05 +/- 0.53 g/dl. All patients 
      were started on 20 U/kg, 3 times/week, to be doubled every 4 weeks if no response 
      was obtained. Five patients had a good response and attained the target Hb of 
      10-12 g/dl and were maintained on low doses of rHuEpo (20 U/kg s.c., twice a 
      week). A marked improvement in haemostatic function was noted when comparing the 
      pre- with the post-treatment measurements. There was a significant reduction in 
      the bleeding time, significant increases in fibrinogen and factor VIII clotting 
      activity but not in von Willebrand factor antigen or ristocetin cofactor. There 
      was also simultaneous enhancement of the platelet aggregation responses to 
      adrenalin, collagen, arachidonic acid and ADP. In conclusion, long-term treatment 
      with small doses of s.c. rHuEpo is safe, convenient and effective in correcting 
      anaemia in patients on CAPD, rHuEpo caused significant improvement of bleeding 
      time which can be explained partly through the correction of anaemia and in part 
      by the improvement in haemostatic function.
FAU - Huraib, S
AU  - Huraib S
AD  - Department of Medicine, College of Medicine and King Khalid University Hospital, 
      Riyadh, Saudi Arabia.
FAU - Gader, A M
AU  - Gader AM
FAU - al-Momen, A K
AU  - al-Momen AK
FAU - Abu-Aisha, H
AU  - Abu-Aisha H
FAU - al-Wakeel, J
AU  - al-Wakeel J
FAU - Memon, N A
AU  - Memon NA
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - 0 (Recombinant Proteins)
RN  - 11096-26-7 (Erythropoietin)
SB  - IM
MH  - Adult
MH  - Anemia/*drug therapy
MH  - Dose-Response Relationship, Drug
MH  - Erythropoietin/adverse effects/*pharmacology
MH  - Hemostasis/*drug effects
MH  - Humans
MH  - Injections, Subcutaneous
MH  - Middle Aged
MH  - *Peritoneal Dialysis, Continuous Ambulatory
MH  - Recombinant Proteins/adverse effects/pharmacology
EDAT- 1995/11/01 00:00
MHDA- 1995/11/01 00:01
CRDT- 1995/11/01 00:00
PHST- 1995/11/01 00:00 [pubmed]
PHST- 1995/11/01 00:01 [medline]
PHST- 1995/11/01 00:00 [entrez]
AID - 10.1159/000217176 [doi]
PST - ppublish
SO  - Haemostasis. 1995 Nov-Dec;25(6):299-304. doi: 10.1159/000217176.